Welcome to our dedicated page for Novo-Nordisk A/S news (Ticker: NVO), a resource for investors and traders seeking the latest updates and insights on Novo-Nordisk A/S stock.
Novo Nordisk A/S (NVO) generates a steady stream of news across diabetes, obesity, rare disease, and cardiometabolic medicine. As a Denmark‑based global healthcare company with B shares listed on Nasdaq Copenhagen and ADRs on the NYSE, its announcements often cover regulatory milestones, clinical trial data, pricing and access initiatives, and strategic corporate actions.
A major focus of recent news is Wegovy (semaglutide), Novo Nordisk’s GLP‑1 therapy for weight management and cardiometabolic risk reduction. Press releases describe FDA approvals for Wegovy injection 2.4 mg in obesity, cardiovascular risk reduction, and metabolic dysfunction‑associated steatohepatitis (MASH), as well as the approval of the once‑daily Wegovy pill, the first oral GLP‑1 medicine for weight management in the US. News coverage also highlights patient access programs, savings offers, and the launch of NovoCare Pharmacy to provide direct‑to‑patient delivery of authentic, FDA‑approved Wegovy.
Investors following NVO news will also see updates on CagriSema and other pipeline assets, including phase 3 data in obesity and cardiovascular risk factors, acquisitions in MASH and rare blood disorders, and broader R&D pipeline progress reported in the company’s financial updates. Corporate governance developments, such as the convening of an Extraordinary General Meeting to elect new board members, and disclosures of share transactions by executives and board members, are reported through Form 6‑K filings.
This news page aggregates these company announcements, clinical and regulatory updates, pricing and access changes, and governance disclosures related to Novo Nordisk A/S. For readers tracking NVO, it provides a focused view of how the company is advancing GLP‑1 therapies, expanding its obesity and cardiometabolic franchise, and managing its global operations and capital markets presence over time.
Summary not available.
Novo Nordisk announced a significant reduction in the U.S. list prices for several insulin products by up to 75%, effective January 1, 2024. The price cuts apply to pre-filled pens and vials of both basal and bolus insulins, including NovoLog, Levemir, and Novolin. This initiative aims to enhance affordability for diabetes patients amidst ongoing healthcare price challenges. Novo Nordisk also offers co-pay support, allowing eligible patients to pay between $25 and $35 for their insulin. The company emphasizes its commitment to making insulin accessible and reducing out-of-pocket costs for patients.
Bigfoot Biomedical has announced the compatibility of its Bigfoot Unity Diabetes Management System with four additional rapid-acting insulin products, including Eli Lilly’s Insulin Lispro and Novo Nordisk’s Insulin Aspart. These insulins are offered at prices at least 50% lower than their branded counterparts, addressing the urgent need for affordable diabetes care. The system, which features smart pen caps compatible with various insulin pens, also includes Lilly’s Lyumjev, available for $35 under the Lilly Insulin Value Program, enhancing access for diabetes patients.
The STEP 5 phase 3b trial results for Wegovy™ (semaglutide) were presented at ObesityWeek 2021. Over two years, 304 adults using Wegovy™ achieved a 15.2% weight loss compared to 2.6% for placebo, with 77.1% of participants losing at least 5% of their body weight. Adverse events included nausea and diarrhea, with 5.9% of Wegovy™ patients discontinuing due to side effects. Approved by the FDA in June 2021, Wegovy™ aims to address the obesity epidemic, which affects more than 42% of adults in the U.S.
Novo Nordisk has announced pivotal results from the STEP clinical development program for semaglutide 2.4 mg, set to be presented at the ENDO Annual Meeting from March 20-23, 2021. The STEP program, involving approximately 4,500 adults, investigates obesity management's efficacy and safety. With findings that could aid in FDA approval, the trials include STEP 1 and STEP 2, focusing on weight loss and cardiometabolic health. The anticipated FDA decision follows a filing in December 2020, highlighting the drug's potential impact on obesity-related health issues.
Novo Nordisk has extended its COVID-19 Patient Assistance Program until June 30, 2021 to help individuals losing health insurance due to job changes from the pandemic. The program offers free insulin for 90 days to eligible patients. Additionally, those enrolled in the My$99Insulin program need to re-register for 2021 eligibility. Novo Nordisk also promotes various affordability initiatives, including the long-standing Patient Assistance Program and Copay Savings Cards. For details on eligibility and options, visit NovoCare.com.
Novo Nordisk has received FDA approval for an updated label for Saxenda® (liraglutide) 3 mg, allowing its use in adolescents (ages 12-17) with obesity. Saxenda, initially approved in 2014 for adults, now addresses a significant and growing need for effective treatments in youth, where obesity rates have doubled. The approval is supported by a phase 3a clinical trial showing significant reductions in BMI and weight compared to placebo. Common side effects include gastrointestinal issues. This move highlights the company's commitment to addressing adolescent obesity.